Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  241.73
-1.28 (-0.53%)
AAPL  258.28
+1.84 (0.72%)
AMD  252.18
-0.56 (-0.22%)
BAC  53.08
+1.27 (2.45%)
GOOG  338.66
+2.38 (0.71%)
META  738.31
+69.58 (10.40%)
MSFT  433.50
-48.13 (-9.99%)
NVDA  192.51
+0.99 (0.52%)
ORCL  169.01
-3.79 (-2.19%)
TSLA  416.56
-14.90 (-3.45%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.